Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ASTER: Anifrolumab Study for Treatment Effectiveness in the Real World Multi-National, Observational, Post-Launch Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice

NCT05637112 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05637112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05637112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ASTER: Anifrolumab Study for Treatment Effectiveness in the Real World Multi-National, Observational, Post-Launch Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
February 27, 2023
Completion date
December 30, 2030
Enrollment
551 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus